Filing Details

Accession Number:
0001610717-25-000027
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-02-20 17:11:53
Reporting Period:
2025-02-18
Filing Date:
2025-02-20
Accepted Time:
2025-02-20 17:11:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1885522 Neumora Therapeutics Inc. NMRA Biological Products, (No Disgnostic Substances) (2836) 844367680
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1992595 Joshua Pinto C/O Neumora Therapeutics, Inc.
490 Arsenal Way, Suite 200
Watertown MA 02472
President No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2025-02-18 8,048 $1.67 76,952 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 138,965 Indirect See footnote
Footnotes
  1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 18, 2024 and subsequently amended on May 22, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.
  2. This transaction was executed in multiple trades in prices ranging from $1.66 to $1.6995, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. Shares held by Maple DE Holdings LLC.